Alps Advisors Inc. bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 39,525 shares of the company’s stock, valued at approximately $724,000. Alps Advisors Inc. owned approximately 0.06% of Kura Oncology as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in shares of Kura Oncology by 203.3% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,820 shares of the company’s stock worth $29,000 after acquiring an additional 1,220 shares in the last quarter. Prospera Financial Services Inc bought a new position in shares of Kura Oncology in the 1st quarter worth $86,000. Denali Advisors LLC raised its position in shares of Kura Oncology by 71.1% in the 2nd quarter. Denali Advisors LLC now owns 6,500 shares of the company’s stock worth $119,000 after acquiring an additional 2,700 shares in the last quarter. Amalgamated Bank bought a new position in shares of Kura Oncology in the 1st quarter worth $123,000. Finally, Principal Financial Group Inc. bought a new position in shares of Kura Oncology in the 2nd quarter worth $198,000.
Wall Street Analysts Forecast Growth
KURA has been the subject of several recent research reports. Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Thursday, August 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, September 21st. Finally, StockNews.com assumed coverage on Kura Oncology in a research note on Wednesday, October 12th. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.
Kura Oncology Trading Up 0.1 %
Kura Oncology (NASDAQ:KURA – Get Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.04. As a group, analysts expect that Kura Oncology, Inc. will post -2.12 earnings per share for the current fiscal year.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
- Get a free copy of the StockNews.com research report on Kura Oncology (KURA)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.